595 related articles for article (PubMed ID: 9240729)
1. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
2. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
3. Skeletal responsiveness to thyroid hormone is not altered at menopause.
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
Bone; 1996 Nov; 19(5):557-64. PubMed ID: 8922657
[TBL] [Abstract][Full Text] [Related]
4. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
Seibel MJ; Cosman F; Shen V; Gordon S; Dempster DW; Ratcliffe A; Lindsay R
J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
[TBL] [Abstract][Full Text] [Related]
5. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
Cosman F; Nieves J; Shen V; Lindsay R
J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
[TBL] [Abstract][Full Text] [Related]
6. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
Kassem M; Brixen K; Blum WF; Mosekilde L; Eriksen EF
J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
[TBL] [Abstract][Full Text] [Related]
7. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
[TBL] [Abstract][Full Text] [Related]
8. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
[TBL] [Abstract][Full Text] [Related]
9. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients.
Scillitani A; Chiodini I; Carnevale V; Giannatempo GM; Frusciante V; Villella M; Pileri M; Guglielmi G; Di Giorgio A; Modoni S; Fusilli S; Di Cerbo A; Liuzzi A
J Bone Miner Res; 1997 Oct; 12(10):1729-36. PubMed ID: 9333135
[TBL] [Abstract][Full Text] [Related]
10. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
11. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
12. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
Hannon R; Blumsohn A; Naylor K; Eastell R
J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
[TBL] [Abstract][Full Text] [Related]
13. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
14. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
[TBL] [Abstract][Full Text] [Related]
16. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
[TBL] [Abstract][Full Text] [Related]
17. The usefulness of biochemical bone markers in predicting the response of hormone replacement therapy in perimenopausal cigarette smoking healthy women.
Cubrilo-Turek M; Stavljenić-Rukavina A; Turek S; Kusec V; Duraković Z
Coll Antropol; 1999 Jun; 23(1):195-201. PubMed ID: 10402723
[TBL] [Abstract][Full Text] [Related]
18. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.
Välimäki MJ; Tiihonen M; Laitinen K; Tähtelä R; Kärkkäinen M; Lamberg-Allardt C; Mäkelä P; Tunninen R
J Bone Miner Res; 1994 May; 9(5):631-7. PubMed ID: 8053391
[TBL] [Abstract][Full Text] [Related]
20. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
